OneMedNet (ONMD) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 Sep, 2026Opening remarks and agenda
Meeting called to order with agenda and rules posted online for orderly conduct.
Attendees introduced, including board members and executive officers.
Inspector of Election and auditor representatives present to oversee proceedings and answer financial questions.
Shareholder proposals
Four matters presented: election of three Class III directors, ratification of auditor, approval of amended equity incentive plan, and approval of reverse stock split amendment.
No other business was brought forward as per bylaws and proxy materials.
Overview of voting outcomes
Quorum established with over 70% of shares represented.
All four proposals approved: director elections, auditor ratification, equity plan amendment, and reverse stock split authorization.
Final voting results to be filed with the SEC within four business days.
Latest events from OneMedNet
- AI-driven platform delivers live, anonymized healthcare data and diversifies assets with Bitcoin.ONMD
Investor presentation - Healthcare imaging data firm registers major share and warrant resale amid financial strain.ONMD
Registration filing - Healthcare data broker faces liquidity challenges and dilution risk amid strategic pivot.ONMD
Registration filing - Registering over 31M shares and warrants for issuance and resale amid ongoing losses and liquidity risk.ONMD
Registration filing - Registering 11.7M shares for resale amid rapid RWD growth, ongoing losses, and liquidity risks.ONMD
Registration filing - Revenue declined 37% and net loss improved, but liquidity and Nasdaq compliance risks persist.ONMD
Q4 2024 - Registering resale of 11.7M shares amid revenue growth but ongoing liquidity and going concern risks.ONMD
Registration filing - Q3 2024 revenue dropped 56% year-over-year, with ongoing liquidity and financing challenges.ONMD
Q3 2024 - Q2 2025 saw a 32% revenue drop but a $3.0M net profit from debt restructuring gains.ONMD
Q2 2025